Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Erika Morsia, Dorela Lame, Michelangelo Pianelli, Giorgio Gramazio, Sonia More', Shahram Kordasti, Serena Rupoli, Antonella Poloni

Blood (2025) 146 (Supplement 1): 7350.

https://doi.org/10.1182/blood-2025-7350

Published: 2025

Journal Articles

Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab

Erika Morsia, Laura Gurguglione, Riccardo Ceccarelli, Sonia More', Shahram Kordasti, Antonella Poloni, Serena Rupoli

Blood (2025) 146 (Supplement 1): 5430.

https://doi.org/10.1182/blood-2025-5430

Published: 2025

Journal Articles

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Blood (2025) 146 (Supplement 1): 2685.

https://doi.org/10.1182/blood-2025-2685

Published: 2025

Journal Articles

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Blood (2025) 146 (Supplement 1): 3806.

https://doi.org/10.1182/blood-2025-3806

Published: 2025

Journal Articles

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Blood (2025) 146 (Supplement 1): 4002.

https://doi.org/10.1182/blood-2025-4002

Published: 2025

Journal Articles

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Sonia More', Valentina Maria Manieri, Laura Corvatta, Erika Morsia, Shahram Kordasti, Attilio Olivieri, Antonella Poloni, Massimo Offidani

Blood (2024) 144 (Supplement 1): 3323.

https://doi.org/10.1182/blood-2024-205518

Published: 2024

Journal Articles

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

Blood (2024) 144 (Supplement 1): 6664.

https://doi.org/10.1182/blood-2024-199961

Published: 2024

Journal Articles

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Erika Morsia, Paola Ranalli, Stefano Baldoni, Dorela Lame, Sonia More', Gaetano La Barba, Fabiola Saladino, Antonella Poloni, Attilio Olivieri, Serena Rupoli, Mauro Di Ianni, Shahram Kordasti

Blood (2024) 144 (Supplement 1): 6645.

https://doi.org/10.1182/blood-2024-207881

Published: 2024

Journal Articles

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Nico Gagelmann, Barbara Mora, Filippo Branzanti, Alessandro Maria Vannucchi, Massimo Breccia, Giuseppe Alberto Maria Palumbo, Massimiliano Bonifacio, Erika Morsia, Elena Maria Elli, Mario Tiribelli, Giulia Benevolo, Mirko Farina, Fabrizio Pane, Roberto Massimo Lemoli, Giovanni Caocci, Alessia Tieghi, Gianni Binotto, Francesco Cavazzini, Bruno Martino, Alessandro Isidori, Margherita Maffioli, Elisa Rumi, Tiziano Barbui, Francisco Cervantes, Matteo Giovanni Della Porta, Andrew T. Kuykendall, Marianna Caramella, Alessandra Iurlo, Valerio De Stefano, Jean-Jacques Kiladjian, David Ross, Jason Gotlib, Timothy Devos, Marco Ruggeri, Richard T. Silver, Rachel B. Salit, Thomas Schroeder, Carmelo Gurnari, Simona Pagliuca, Christina Rautenberg, Marie Robin, Marie-Thérèse Rubio, Jaroslaw Maciejewski, Alessandro Rambaldi, Maria Chiara Finazzi, Andrea Bacigalupo, Patrizia Chiusolo, Hans Christian Reinhardt, Bart L. Scott, Nicolaus Kröger, Francesco Passamonti, Francesca Palandri

Blood (2024) 144 (Supplement 1): 245.

https://doi.org/10.1182/blood-2024-210804

Published: 2024

Journal Articles

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Blood (2024) 144 (Supplement 1): 242.

https://doi.org/10.1182/blood-2024-200528

Published: 2024

Journal Articles

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Blood (2024) 144 (Supplement 1): 2690.

https://doi.org/10.1182/blood-2024-194413

Published: 2024

Journal Articles

Brentuximab Vedotin in the Treatment of Cutaneuous T Cell Lymphomas: A Multicenter, Retrospective, Case-Control Study from Italy

Erika Morsia, Vieri Grandi, Annagiulia Zizzari, Giacomo Loseto, Paolo Fava, Silvia Alberti Violetti, Alessandro Pileri, Alessandro Broccoli, Paola Vitiello, Antonello Sica, Luca Nassi, Cosimo Di Riamondo, Pietro Quaglino, Nicola Pimpinelli, Emilio Berti, Pier Luigi Zinzani, Serena Rupoli

Blood (2023) 142 (Supplement 1): 6111.

https://doi.org/10.1182/blood-2023-189116

Published: 2023

Journal Articles

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Blood (2023) 142 (Supplement 1): 4713.

https://doi.org/10.1182/blood-2023-189193

Published: 2023

Journal Articles

Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience

Dorela Lame, Marianeve Caprino, Elena Marinelli Busilacchi, Nadia Viola, Erika Morsia, Michelangelo Pianelli, Shahram Kordasti, Attilio Olivieri, Antonella Poloni

Blood (2022) 140 (Supplement 1): 6923–6924.

https://doi.org/10.1182/blood-2022-169820

Published: 2022

Journal Articles

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Erika Morsia, Elena Torre, Francesca Marrara, Sonia Morè, Mauro Petrini, Valentina Maria Manieri, Laura Gurgoglione, Guido Gini, Massimo Offidani, Attilio Olivieri, Serena Rupoli

Blood (2022) 140 (Supplement 1): 11375.

https://doi.org/10.1182/blood-2022-163790

Published: 2022

Journal Articles

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Blood (2022) 140 (Supplement 1): 10027–10028.

https://doi.org/10.1182/blood-2022-168619

Published: 2022

Journal Articles

Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases

Erika Morsia, Elena Torre, Francesca Marrara, Ilaria Battilà, Alessandro Fiorentini, Anna Rita Scortechini, Massimo Offidani, Gianluca Svegliati-Baroni, Emanuele Bendia, Attilio Olivieri, Gianluca Tarantino, Serena Rupoli

Blood (2022) 140 (Supplement 1): 8526–8527.

https://doi.org/10.1182/blood-2022-169449

Published: 2022

Journal Articles

Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas

Silvia Uccella, Gaia Goteri, Antonino Maiorana, Valentina Donati, Maria Grazia Tibiletti, Francesca Magnoli, Sofia Facchi, Deborah Merchiori, Erika Morsia, Robel Papotti, Stefania Bettelli, Elisa Forti, Sara Galimberti, Serena Rupoli, Alessandra Filosa, Dimitri Dardanis, Luca Braglia, Samantha Pozzi, Stefano Sacchi

Blood (2022) 140 (Supplement 1): 11887–11888.

https://doi.org/10.1182/blood-2022-166554

Published: 2022

Journal Articles

Long-Term Efficacy of Psoralen Plus Ultraviolet a Irradiation and Low-Dose Interferon-Alpha Therapy According to Conventional and Emerging Clinical Endopoints of Early Stage Cutaneous T Cell Lymphoma

Serena Rupoli, Gaia Goteri, Erika Morsia, Elena Torre, Kimberly Blaine Garvey, Federica Giantomassi, Anna Campanati, Anna Maria Offidani, Giuliano Brandozzi, Mozzicafreddo Giorgio, Marco Simonacci, Attilio Olivieri

Blood (2021) 138 (Supplement 1): 2462.

https://doi.org/10.1182/blood-2021-150633

Published: 2021

Journal Articles

Expression of Paraoxonase-2 in Different Stages of Cutaneous T Cell Lymphoma: Is It a Potential Biomarker for Aggressiveness?

Erika Morsia, Serena Rupoli, Elisa Molinelli, Davide Sartini, Anna Maria Offidani, Monica Emanuelli, Eleonora Salvolini, Attilio Olivieri, Gaia Goteri

Blood (2021) 138 (Supplement 1): 4496.

https://doi.org/10.1182/blood-2021-150793

Published: 2021

Update search

NARROW

Publications

Format

Article Type

Date

Availability

Extended validation of the RR6 prognostic model at 6 and 12 months in primary and secondary myelofibrosis patients treated with ruxolitinib

Cytokine signatures predict response, progression, and immune-related toxicity in Sézary syndrome patients treated with mogamulizumab

Health-related quality of life and symptom burden of patients with vexas: Real-world data from a multicenter observational study

Prognostic impact of persistent and treatment-emergent cytopenia in 879 myelofibrosis patients treated with ruxolitinib: The “RUX-MF” study

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025: A real life multicentre analysis in Italy

Could Clinical-Laboratory Features Recognize Functional High Risk Multiple Myeloma Patients? a Real-World Analysis

Cytopenias and Failure to Use Innovative Therapy Are Main Drivers of Worse Outcome after Discontinuation of Ruxolitinib in Myelofibrosis

The Role of TET2 Mutation in Patients with Myeloproliferative Neoplasms and Thrombosis in Unusual Sites (Splanchnic Thrombosis and Cerebral Thrombosis)

Personalized Transplant Decision Making for Myelofibrosis in the Era of Molecular Genetics and JAK Inhibition

Revised ELN Criteria in Polycythemia Vera Identify an Increased Risk Phenotype for Thrombotic Events Beyond Conventional Risk Stratification. a Multicenter Cooperative Study

Methodology and Clinical Significance of Longitudinal UBA1 Clonal Burden Evaluation in Vexas Syndrome

Brentuximab Vedotin in the Treatment of Cutaneuous T Cell Lymphomas: A Multicenter, Retrospective, Case-Control Study from Italy

Updated Analysis of a Prospective, Multicenter, Observational Study on the Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma

Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience

Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis

Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study

Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases

Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas

Long-Term Efficacy of Psoralen Plus Ultraviolet a Irradiation and Low-Dose Interferon-Alpha Therapy According to Conventional and Emerging Clinical Endopoints of Early Stage Cutaneous T Cell Lymphoma

Expression of Paraoxonase-2 in Different Stages of Cutaneous T Cell Lymphoma: Is It a Potential Biomarker for Aggressiveness?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only